Vol 4 n° 4 - Drug Development
Past issues Contributors How to publish Contributions and comments Home
 
C o n t e n t s ISSUE COORDINATED BY: Jean-Paul MACHER Special indications Challenges in the development of clinical trials for major depressive disorder: lessons learned from trials in minor depression Mark Rapaport, Rachel E. Maddux Research on serotonin and suicidal behavior: neuroendocrine and molecular approaches Humberto Corrêa, Marco Aurélio Romano-Silva, Fabrice Duval, Ana Carolina Campi-Azevedo, Vivtor Lima, Jean-Paul Macher Interaction between the serotonergic system and HPA and HPT axes in patients with major depression: implications for pathogenesis of suicidal behavior Fabrice Duval, Marie-Claude Mokrani, José Monreal, Thomas Weiss, Said Fattah, Béatrice Hamel, Jean-Paul Macher Developments in antipsychotic therapy with regard to hypotheses for schizophrenia Manfred Ackenheil, Klaus Weber Studies in schizophrenia: pathophysiology and treatment Carol A. Tamminga, Deborah R. Medoff Optimizing dosing in atypical neuroleptic monotherapy Fabien Trémeau, Leslie Citrome Anatomic magnetic resonance imaging studies of attention-deficit/ hyperactivity disorder Francisco Xavier Castellanos Regulatory issues Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern Rashmi Shah Study designs, duration, and choice of comparators including the use of placebo John A. Lewis Japanese pharmaceutical and regulatory environment Ryoichi Nagata, Jean-David Rafizadeh-Kabe